Inovio Pharmaceuticals
Inovio is a US company developing DNA medicines delivered by electroporation, whose lead cancer-related programme VGX-3100 treats the HPV-caused precancerous cervical lesions that lead to cervical cancer.
Overview
Inovio Pharmaceuticals, listed on Nasdaq, develops DNA plasmid immunotherapies and vaccines delivered into muscle or skin with a hand-held electroporation device. Its most advanced programme, VGX-3100, targets HPV 16 and 18 to clear high-grade cervical dysplasia (CIN2/3), the precancerous lesion that precedes cervical cancer, and completed the phase 3 REVEAL trials; the company has also run trials of DNA vaccines in HPV-related head and neck and anal cancers and in glioblastoma. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- CompanyAveta Biomics
Shares Glioma & glioblastoma, Head and neck squamous cell carcinoma and the tag ctgov-sponsor.
- CompanyNeonc Technologies
Shares Glioma & glioblastoma, Cervical cancer, Head and neck squamous cell carcinoma and the tag ctgov-sponsor.
- CompanyQBiotics
Shares Head and neck squamous cell carcinoma and the tag ctgov-sponsor.
- CompanyBio-Thera Solutions
Shares Cervical cancer and the tag ctgov-sponsor.
- CompanyRakuten Medical
Shares Head and neck squamous cell carcinoma and the tag ctgov-sponsor.
- CompanyHangzhou Hanx Biopharmaceuticals
Shares Glioma & glioblastoma and the tag ctgov-sponsor.
- CompanyAP Biosciences
Shares Head and neck squamous cell carcinoma and the tag ctgov-sponsor.
- CompanyTiumBio
Shares Head and neck squamous cell carcinoma and the tag ctgov-sponsor.